%20--%3e%3csvg%20width='63.297821mm'%20height='39.29665mm'%20viewBox='0%200%2063.297821%2039.29665'%20version='1.1'%20id='svg8765'%20inkscape:version='1.1%20(c4e8f9ed74,%202021-05-24)'%20sodipodi:docname='OBALogoSingle2.svg'%20xmlns:inkscape='http://www.inkscape.org/namespaces/inkscape'%20xmlns:sodipodi='http://sodipodi.sourceforge.net/DTD/sodipodi-0.dtd'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:svg='http://www.w3.org/2000/svg'%3e%3csodipodi:namedview%20id='namedview8767'%20pagecolor='%23ffffff'%20bordercolor='%23666666'%20borderopacity='1.0'%20inkscape:pageshadow='2'%20inkscape:pageopacity='0.0'%20inkscape:pagecheckerboard='0'%20inkscape:document-units='mm'%20showgrid='false'%20fit-margin-top='0'%20fit-margin-left='0'%20fit-margin-right='0'%20fit-margin-bottom='0'%20inkscape:zoom='1.1759259'%20inkscape:cx='179.85827'%20inkscape:cy='102.04724'%20inkscape:window-width='1920'%20inkscape:window-height='972'%20inkscape:window-x='0'%20inkscape:window-y='27'%20inkscape:window-maximized='1'%20inkscape:current-layer='layer1'%20/%3e%3cdefs%20id='defs8762'%20/%3e%3cg%20inkscape:label='Layer%201'%20inkscape:groupmode='layer'%20id='layer1'%20transform='translate(-31.351095,-50.101677)'%3e%3cpath%20style='fill:none;stroke:%233584e4;stroke-width:3.965;stroke-linecap:square;stroke-linejoin:round;stroke-miterlimit:4;stroke-dasharray:none;stroke-opacity:1'%20d='m%2077.07508,77.78787%2014.84134,8.87817%20V%2052.83397%20L%2034.08359,86.5521%20V%2053.69366%20l%2015.27351,9.31107'%20id='path8388'%20sodipodi:nodetypes='cccccc'%20/%3e%3c/g%3e%3c/svg%3e)
Maze Therapeutics, Inc. Common Stock(MAZE) Stock Analysis | Healthcare
Market Performance
Stock returned +10.0% over the past year, broadly in line with market conditions.Analyst Target
Analyst consensus price target: $62.55.What is Maze Therapeutics, Inc. Common Stock?
, a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
MAZE · Verdict
Limited reward · low risk
MAZE stands out on balance sheet and volatility, but watch the cash flow signal.
Based on 88% data coverage
MAZE · Verdict
What’s working & what to watch
Strengths 3
- Balance sheet100/100
Current ratio 15.50
- Volatility95/100
Top decile vs peers
- Valuation73/100
P/E 8.5×
Watchouts 3
- Cash flow5/100
Weak vs peers
- Profitability10/100
-37% return on equity
- Growth31/100
Earnings +4.5% CAGR
Model-based scoring. For information only — not financial advice.
What is Maze Therapeutics, Inc. Common Stock?
, a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.52B.
Financial Highlights
Investment Breakdown
Analysis
Reward: Moderate (38)The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.
Similar stocks to compare
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.
| Shares sold | Shares bought | |
|---|---|---|
| 0-3months | 0 | 0 |
| 3-6months | 462,500 shares $2.8M | 0 |
| 6-9months | 13200,000 shares $8.3M | 0 |
| 9-12months | 120,744 shares $464k | 0 |